On May 28, at the headquarters of the Ministry of Health, Assoc. Prof. Dr. Vu Manh Ha, Alternate Member of the Central Committee of the Communist Party and Permanent Vice Minister of Health, hosted a high-level bilateral working session with an executive delegation from Johnson & Johnson (J&J), led by Sarthak Bhaskar Ranade, Regional Managing Director for India and Southeast Asia. The summit targeted strategic alignment on institutional policy optimization, advanced medical technology integration, healthcare financing sustainability, and the systematic expansion of clinical treatment access for patients across Vietnam.
The primary policy frameworks, structural financial proposals, and public-private partnership mechanisms outlined during the session feature:
-
Strategic Directives of Vietnam’s Healthcare System: Permanent Vice Minister Vu Manh Ha stated that Vietnam is entering a transformative development phase aimed at configuring an equitable, premium-quality, efficient, and sustainable healthcare system with a strict patient-centric orientation. The Ministry of Health is currently prioritizing legislative updates, reinforcing universal health insurance sustainability, driving digital transformation, and encouraging the structured, responsible participation of multinational corporations to mobilize complementary resources for public care.
-
Healthcare Financing Frameworks Proposed by J&J: Sarthak Bhaskar Ranade reaffirmed the conglomerate’s global mandate to leverage innovative medicine and medtech to intercept and cure complex diseases via minimally invasive and highly personalized interventions. J&J executives presented targeted strategic proposals to the Ministry, focusing on the mechanism of integrating supplementary private health insurance models atop the existing public national health insurance baseline, alongside developing public-private partnership (PPP) models to co-share treatment costs within oncology, hematology, and rare disease sectors.
-
Interventions for High-Cost Critical Pathologies: Enrolled technical experts from both entities analyzed methods to scale up scientific exchanges and clinical research participation to facilitate early disease detection. These structural adjustments in health insurance reimbursement criteria are projected to mitigate severe financial burdens for patients managing critical illnesses, while streamlining the clinical adoption of novel, innovative breakthrough therapies within the domestic market.
-
Operational Execution and Regulatory Review Track: Acknowledging the highly technical and policy-intensive nature of J&J’s recommendations, Vice Minister Vu Manh Ha reiterated that the Ministry welcomes constructive, innovation-driven initiatives from the international corporate community. Moving forward, the Health Insurance Department, the Financial Planning Department, and related functional authorities will directly interface with J&J’s technical teams to investigate, evaluate, and potentially incorporate these research tracks into ongoing macro-level statutory policy revisions.
Executive leadership from the Ministry of Health highly commended Johnson & Johnson’s sustained 30-year operational footprint in Vietnam, specifically highlighting its contributions to pharmaceuticals, medical devices, and professional capacity-building programs for domestic healthcare practitioners. The Ministry looks forward to J&J continuous development of long-term investment portfolios that directly align with the overarching structural development strategy of Vietnam’s healthcare infrastructure.